Company Update (NASDAQ:IONS): Ionis Pharmaceuticals Inc Licenses First Oral Antisense Drug Acting Locally in the GI Tract to Janssen

Ionis Pharmaceuticals Inc (NASDAQ:IONS) announced that it has earned $10 millionfrom Janssen Biotech, Inc. (Janssen) upon licensing IONIS-JBI1-2.5Rx, an orally delivered antisense drug designed to locally inhibit an undisclosed target in the gastrointestinal (GI) tract for the treatment of a GI autoimmune disease.  Janssen will assume all global development, regulatory and commercialization responsibilities for IONIS-JBI1-2.5Rx once Ionis completes the IND-enabling studies.

“IONIS-JBI1-2.5Rx is the first antisense drug to enter development as part of Ionis’ collaboration with Janssen to discover and develop orally administered, locally acting RNA-targeted therapeutics for autoimmune diseases in the gastrointestinal tract.  We are very pleased to have rapidly advanced this first drug candidate into development within a year and a half of initiating our collaboration with Janssen,” said B. Lynne Parshall, chief operating officer at Ionis Pharmaceuticals.  “This new drug further expands our technology’s reach into a new therapeutic setting and a new route of delivery.”

Under the terms of the agreement, which covers three programs, Ionis is eligible to receive nearly $800 million in development, regulatory and sales milestone payments and license fees for these programs.  In addition, Ionis will receive tiered royalties that on average are double-digits on sales from any product that is successfully commercialized. (Original Source)

Shares of Ionis closed yesterday at $27.69, up $0.41 or 1.50%. IONS has a 1-year high of $62.68 and a 1-year low of $19.59. The stock’s 50-day moving average is $23.48 and its 200-day moving average is $35.45.

On the ratings front, Ionis has been the subject of a number of recent research reports. In a report issued on July 14, Jefferies Co. analyst Eun Yang reiterated a Sell rating on IONS, with a price target of $12, which represents a potential downside of 56.7% from where the stock is currently trading. Separately, on the same day, Leerink Swann’s Michael Schmidt reiterated a Hold rating on the stock and has a price target of $26.

According to, which ranks over 7,500 financial analysts and bloggers to gauge the performance of their past recommendations, Eun Yang and Michael Schmidt have a total average return of -0.8% and 7.1% respectively. Yang has a success rate of 56.5% and is ranked #2978 out of 4064 analysts, while Schmidt has a success rate of 56.2% and is ranked #533.

The street is mostly Neutral on IONS stock. Out of 8 analysts who cover the stock, 4 suggest a Hold rating , 3 suggest a Buy and one recommends to Sell the stock. The 12-month average price target assigned to the stock is $26.00, which reflects a potential downside of -6.1% from last closing price.

Ionis Pharmaceuticals, Inc. engages in the development and commercialization of antisense drug discovery platform. It operates through the Drug Discovery and Development segment which exploits a novel drug discovery platform created to generate a broad pipeline of first-in-class drugs for the company and its partners. Its products are used to treat diseases such as severe and rare, cardiovascular, neurologic and metabolic diseases, and cancer. 


Stay Ahead of Everyone Else

Get The Latest Stock News Alerts